Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML | Synapse

October 30, 2019Open Access

Ver artículo completo

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

APAlexander E. PerlUniversity of Pennsylvania

Giovanni MartinelliUniversity of Siena

Jorge E. CortésAugusta University Health

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory FLT3-mutated AML. (Funded by Astellas Pharma; ADMIRAL ClinicalTrials.gov number, NCT02421939.).

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Perl et al. (Wed,) studied this question.

synapsesocial.com/papers/69d843a48cb8f39931ae2aa8 https://doi.org/https://doi.org/10.1056/nejmoa1902688

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial2019 · 485 citations
2Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia2019 · 442 citations
3Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.1996 · 1,173 citations
4Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia2003 · 2,668 citations
5Genomic Classification and Prognosis in Acute Myeloid Leukemia2016 · 4,412 citations